Introduction
Leading European ophthalmology company VISUfarma B.V., offering over 60 specialty eye care products, will be acquired by a global pharma subsidiary for €190 million (₹1,960 crore), expanding its presence across major European markets.
Also Read: AWL Agri Business: Stock jumps after signing MoU with Sea and Solidaridad
Share price movement of Lupin
On September 29, 2025, Lupin Ltd opened at ₹1,922.65, up 0.11% from its previous close of ₹1,920.75. The stock reached a high of ₹1,957.50 and a low of ₹1,922.10. By 1:26 PM, it traded at ₹1,937.70, a 0.88% increase, with a market cap of ₹88,505.97 crore.
Lupin Acquires VISUfarma to Expand Ophthalmology Business
Lupin Limited announced that its wholly owned subsidiary, Nanomi B.V., will acquire VISUfarma B.V., a Netherlands-based specialty ophthalmology company. The acquisition aligns with Lupin’s strategy to expand its European footprint.
VISUfarma operates across Italy, the UK, Spain, Germany, and France. It offers over 60 branded products in dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and nutraceuticals prescribed by ophthalmologists.
The enterprise value of the acquisition is €190 million (approximately ₹1,960 crore). Lupin will fund it with existing cash. The deal is expected to close by the end of 2025, subject to regulatory approvals.
Stock performance of Lupin for Period of 1 week, 6 months, and 1 year
Lupin Ltd delivered a negative return of 4.22% over the past week and declined by 4.47% in the past six months. The stock fell 13.5% over the past year.
Also Read: Highway Infrastructure: Stock jumps after securing ₹31 Cr contract
Shareholding pattern of Lupin
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
| Promoter | 46.90% | 46.90% | 47.00% |
| FII | 21% | 22% | 22% |
| DII | 25.60% | 25.40% | 24.70% |
| Public | 6.30% | 6% | 6.30% |
About Lupin
Lupin Limited (NSE: LUPIN) is a global pharmaceutical leader from Mumbai, offering branded and generic formulations, complex generics, and biotech products across 100+ markets, with 15 manufacturing sites, 7 research centers, and 24,000 employees.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
A: Lupin Limited’s share price rose following the announcement of acquiring VISUfarma B.V. for €190 million (₹1,960 crore).
A: Lupin Limited has a market capitalization of approximately ₹88,505.97 crore as of September 29, 2025.
A: Lupin Limited operates in pharmaceuticals, including branded and generic formulations, complex generics, biotechnology, and active pharmaceutical ingredients.
